13 September 2020 : Database Analysis
Nomogram for Predicting Breast Cancer-Specific Mortality of Elderly Women with Breast Cancer
Xunxi Lu12ABCDEF, Xiaoguang Li1ADEFG, Hong Ling12DFG, Yue Gong12ACD, Linwei Guo12ACE, Min He12DF, Hefen Sun12DG, Xin Hu12EFG*DOI: 10.12659/MSM.925210
Med Sci Monit 2020; 26:e925210
Table 3 Proportional subdistribution hazard model of probabilities of BCSD for patients in the training cohort.
Characteristics | Coefficient | sdHR (95% CI) | P-value |
---|---|---|---|
Age | |||
65–74 | Reference | ||
75+ | 0.360 | 1.43 (1.30–1.58) | <0.001 |
Marriage | |||
Unmarried | Reference | ||
Married | −0.314 | 0.73 (0.65–0.82) | <0.001 |
Race | |||
White | Reference | ||
Black | 0.482 | 1.62 (1.38–1.90) | <0.001 |
Other* | −0.108 | 0.90 (0.74–1.09) | 0.280 |
Histology | |||
IDC | Reference | ||
ILC | 0.100 | 1.11 (0.94–1.29) | 0.210 |
Other** | −0.332 | 0.72 (0.63–0.82) | <0.001 |
Grade | |||
I | Reference | ||
II | 1.030 | 2.80 (2.33–3.37) | <0.001 |
III/IV | 1.980 | 7.25 (6.07–8.66) | <0.001 |
ER status | |||
Negative | Reference | ||
Positive | −1.107 | 0.33 (0.20–0.37) | <0.001 |
PR status | |||
Negative | Reference | ||
Positive | −0.969 | 0.38 (0.35–0.42) | <0.001 |
T stage | |||
T1 | Reference | ||
T2 | 1.383 | 3.99 (3.59–4.43) | <0.001 |
T3 | 2.130 | 8.41 (7.14–9.91) | <0.001 |
T4 | 2.506 | 12.30 (10.20–14.70) | <0.001 |
N stage | |||
N0 | Reference | ||
N1 | 1.245 | 3.47 (3.11–3.88) | <0.001 |
N2 | 1.472 | 4.36 (3.83–4.96) | <0.001 |
N3 | 1.589 | 4.90 (4.30–5.58) | <0.001 |
Surgery | |||
BCS | Reference | ||
Mastectomy | 1.035 | 2.81 (2.56–3.1) | <0.001 |
IDC – infiltrating ductal carcinoma; ILC – infiltrating lobular carcinoma; ER – estrogen receptor; PR – progesterone receptor; BCS – breast-conserving surgery; BCSD – breast cancer-specific death; OCSD – other cause-specific death; HR – subdistribution hazard ratio; CI – confidence interval; T – tumor stage; N – nearby lymph node stage. * Including American Indian/Alaskan native and Pacific Islander; ** including other histology of invasive breast cancer except IDC and ILC. |